pioneer 9 semaglutide Efficacy and safety of once-daily oral 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial A1C & Weight Results |

In our current analysis of the STEP 1 data, we found evidence that semaglutide might lower CVD risk even in populations not enriched for multiple CVD risk factors or with established CVD (primary prevention)

Manandhar B, Ahn JM

Novo Nordisks filing strategy shows that patenting does not and should not stop after protection of the core concept

Tirzepatide activates GIP receptors that semaglutide does not touch, meaning your body has zero tolerance to this new receptor pathway

Calculate your weekly usage and plan your reconstitution around the 28-day expiration window

Lessons from these litigation stories should be drawn upon now to draft strong patent applications that will weather the inevitable future challenges